3SBio Inc. is a leading biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative therapies. Serving patients globally, the company operates primarily in the biopharmaceutical market, targeting unmet medical needs in oncology, nephrology, dermatology, and autoimmune diseases. With a robust pipeline of nearly 30 listed products and 25 candidate products, 3SBio leverages advanced technology and international partnerships to drive growth and enhance patient outcomes. The business model centers on developing proprietary drugs and biosimilars, generating revenue through product sales and licensing agreements. In 2021, 3SBio reported an operating income of approximately RMB 3.11 billion, reflecting a 15.3% year-over-year increase, and a net profit of RMB 90 billion, up 28%. The company's commitment to innovation, patient care, and global expansion underpins its market leadership and sustained financial performance.

Keywords: biopharmaceutical, oncology, nephrology, dermatology, autoimmune, proprietary drugs, biosimilars, innovation, patient care, global expansion.